Ryvu Therapeutics S.A. (WSE:RVU)
Poland
· Delayed Price · Currency is PLN 25.50
-0.05 (-0.20%)
At close: Mar 9, 2026
Ryvu Therapeutics Revenue
Ryvu Therapeutics had revenue of 19.50M PLN in the quarter ending September 30, 2025, a decrease of -22.12%. This brings the company's revenue in the last twelve months to 90.41M, down -0.84% year-over-year. In the year 2024, Ryvu Therapeutics had annual revenue of 101.96M with 51.51% growth.
Revenue (ttm)
90.41M
Revenue Growth
-0.84%
P/S Ratio
6.52
Revenue / Employee
275.64K
Employees
328
Market Cap
589.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 101.96M | 34.67M | 51.51% |
| Dec 31, 2023 | 67.30M | -1.14M | -1.67% |
| Dec 31, 2022 | 68.44M | 33.02M | 93.25% |
| Dec 31, 2021 | 35.41M | -1.54M | -4.16% |
| Dec 31, 2020 | 36.95M | 3.23M | 9.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Captor Therapeutics Spolka Akcyjna | 7.57M |
| BIOTON | 282.52M |
| Synthaverse | 71.76M |
| Molecure | 5.86M |
| Mabion | 14.81M |
| Poltreg | 250.00K |
| NanoGroup | -6.90K |
| Urteste | 1.80M |